Events

2012 JP Morgan Healthcare Reception

January 9, 2012

Press Club , San Francisco, California

Summary

Goodwin Procter's Life Sciences Practice will host its annual reception in conjunction with the JP Morgan Healthcare Conference in San Francisco, CA. The reception is expected to draw nearly 500 life sciences industry executives and investors.

Related Content

Goodwin Insights
March 21, 2023
R&W Insurance Coverage for Healthcare Services Transactions
Alert
March 15, 2023
The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies
Alert
March 14, 2023
HHS to Create New Potential Medicare Pricing Models for Cell and Gene Therapy, Drugs Subject to Accelerated FDA Approval, and “High-Value” Generics
Alert
March 8, 2023
DOJ Revises Corporate Compliance Guidance to Take on Compensation Incentives and Communications Preservation — With a Continued Emphasis on Individual Accountability
Goodwin Insights
March 2, 2023
A Recap of Resilience: Goodwin’s Life Sciences Practice
Goodwin Insights
March 2, 2023
2022 Year in Review: Securities Litigation Against Life Sciences Companies
Big Molecule Watch
February 28, 2023
EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®
Alert
February 28, 2023
DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting

2012 JP Morgan Healthcare Reception

Summary

Related Content

R&W Insurance Coverage for Healthcare Services Transactions

The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies

HHS to Create New Potential Medicare Pricing Models for Cell and Gene Therapy, Drugs Subject to Accelerated FDA Approval, and “High-Value” Generics

DOJ Revises Corporate Compliance Guidance to Take on Compensation Incentives and Communications Preservation — With a Continued Emphasis on Individual Accountability

A Recap of Resilience: Goodwin’s Life Sciences Practice

2022 Year in Review: Securities Litigation Against Life Sciences Companies

EMA Adopts Positive Opinion for Amgen’s Eculizumab Biosimilar Candidate BEKEMV®

DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting

The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

Moderna and Generation Bio Announce $76 Million Strategic Collaboration to Develop Non-Viral Genetic Medicines

Nicole Daley Honored by the 2023 Massachusetts Lawyers Weekly Excellence in the Law Awards

Goodwin named in Top 3 for US Private Equity Debt Deals in 2022

Biopharma Industry Sharply Divided Over Supreme Court Antibody Patent Brawl (Pink Sheet)

Goodwin Snags Tech and Life Sciences Litigation Trio (Commercial Dispute Resolution)

Goodwin Adds 3 IP Litigators In NY (Law360)

Goodwin Grows New York IP Litigation Practice by Three Partners (Bloomberg Law)

Life Sciences